Elekta (STO:EKTA B) today said it’s delaying the rollout of its Unity device, designed to combine magnetic resonance imaging with a linear accelerator for radiation therapy, saying it needs more time to finalize and validate the linac control system.
The Swedish company said the decision means it’s postponing its bid for CE Mark approval in the European Union until the first half of next year.
“We are convinced that the new technology will revolutionize radiation therapy and create completely new opportunities for physicians and their patients. With the shift in CE Mark and FDA submission, we adjust our target for the first 75 orders accordingly to the first half of calendar year 2020,” CEO Richard Hausmann said in prepared remarks.
Elekta also posted fiscal second-quarter results that topped analysts’ estimates. Profits for the three months ended Oct. 30 were SEK247 million (about $29.5 million), or SEK0.65 per share (8¢), on sales of SEK2.80 billion ($334.7 million). That amounts to profit growth of nearly 350% on sales growth of 15.1% compared with fiscal Q2 last year.
Analysts were looking for EPS of SEK0.52 (6¢) on sales of SEK2.64 billion ($315.4 million).
EKTA B shares were up 0.2% to SEK70.20 ($8.39) apiece today in mid-afternoon trading in Stockholm.
($1 = SEK8.37215)